From CTV News:
A federal body that reviews medications has recommended that a high-cost drug for treating one form of the leading cause of vision loss among older Canadians be covered by provincial insurance plans.
The Common Drug Review recommended Friday that provincial drug plans cover the drug Lucentis for the "wet" form of age-related macular degeneration, but limit coverage to 15 vials "to treat the better-seeing eye."
The CDR said Lucentis has been shown to be effective in stabilizing and improving sight in people with wet macular degeneration. ...more
Showing posts with label Common Drug Review. Show all posts
Showing posts with label Common Drug Review. Show all posts
Sunday, March 30, 2008
Monday, May 07, 2007
Agency decisions threaten cancer patient health: doc
From the Edmonton Sun:
An Edmonton doctor says the health of Canadian cancer patients is being threatened by a government-appointed agency that makes decisions on provincial drug funding.
The Common Drug Review (CDR) is using a decision-making process that is flawed, said Dr. Scott North, a medical oncologist at the Cross Cancer Institute.
North explained that the CDR recently reviewed two new drugs for the treatment of kidney cancer.
One of the drugs, Nexavar, was found to be especially effective halfway through one recent clinical trial, North said. ...more
An Edmonton doctor says the health of Canadian cancer patients is being threatened by a government-appointed agency that makes decisions on provincial drug funding.
The Common Drug Review (CDR) is using a decision-making process that is flawed, said Dr. Scott North, a medical oncologist at the Cross Cancer Institute.
North explained that the CDR recently reviewed two new drugs for the treatment of kidney cancer.
One of the drugs, Nexavar, was found to be especially effective halfway through one recent clinical trial, North said. ...more
Subscribe to:
Posts (Atom)
